Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer

NCT04493060 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04493060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04493060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2020
Completion date
June 1, 2025
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma, stage iv pancreatic cancer ajcc v8